Back to Search
Start Over
Qualitative and Quantitative Assessment of Patient and Carer Experience of Chemotherapy (Docetaxel) in Combination with Androgen Deprivation Therapy (ADT) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Source :
- Advances in Therapy
- Publication Year :
- 2018
-
Abstract
- Introduction Recent studies suggest that docetaxel plus androgen deprivation therapy can prolong survival among men with metastatic hormone-sensitive prostate cancer (mHSPC). However, as a cytotoxic therapy, there is a need to understand the experiences of men with mHSPC receiving docetaxel and their carers in a real-world setting. Methods During phase 1, semi-structured qualitative interviews were conducted with men with mHSPC (n = 31) and their carers (n = 14) in Europe to elicit in-depth data concerning their experiences with docetaxel. Eighteen men were also asked to record their experiences in a diary for 7 days. During phase 2, men with mHSPC (n = 161) and carers of men with mHSPC (n = 135) completed an online survey comprising self-report questionnaires including the Cancer Therapy Satisfaction Questionnaire, Brief Fatigue Inventory, Functional Assessment of Cancer Therapy-Prostate, EuroQol-5-Dimensions and the Burden Scale for Family Caregivers (carers only). Results At the outset of therapy, men reported a willingness to take docetaxel to prolong their life, despite being fearful of the potential side effects and impacts on their daily lives. Patient and carer experiences were generally consistent with pre-treatment expectations. However, variations in individual experiences and their ability to tolerate side effects were evident. Fatigue emerged as a prominent symptom with the majority (n = 98, 60.9%) of men reporting experiencing moderate-severe fatigue in the past 24 h. Participant ratings of fatigue were strongly correlated with health-related quality of life (r = − 0.82). Nausea, diarrhoea and sore mouth were also among the most bothersome symptoms for participants. Conclusions Findings from this study highlight that real-world experience of docetaxel may differ from that observed in clinical trials and that care must be taken to ensure that treatment options are tailored to the needs of individual patients to promote not only how long patients survive but also the quality of that survival. Funding Janssen
- Subjects :
- Adult
Male
medicine.medical_specialty
Carers
medicine.medical_treatment
Health-related quality of life
Antineoplastic Agents
Docetaxel
Disease-Free Survival
Androgen deprivation therapy
03 medical and health sciences
Prostate cancer
0302 clinical medicine
Quality of life (healthcare)
Medicine
Humans
Pharmacology (medical)
030212 general & internal medicine
Neoplasm Metastasis
Aged
Original Research
Aged, 80 and over
Chemotherapy
Treatment satisfaction
Family caregivers
business.industry
Cancer
Prostatic Neoplasms
Androgen Antagonists
General Medicine
Middle Aged
medicine.disease
Clinical trial
Europe
Cross-Sectional Studies
Caregivers
Patient Satisfaction
030220 oncology & carcinogenesis
Metastatic hormone-sensitive prostate cancer
Physical therapy
Quality of Life
Self Report
business
medicine.drug
Subjects
Details
- ISSN :
- 18658652
- Volume :
- 35
- Issue :
- 12
- Database :
- OpenAIRE
- Journal :
- Advances in therapy
- Accession number :
- edsair.doi.dedup.....55671be0d56a6de8f010817735102475